Published in Hepatitis Weekly, September 3rd, 2001
Those researchers, members of a North American research consortium, developed a decision analysis model to predict costs and lifetime outcomes when administering a 2-dose hepatitis B virus (HBV) vaccine regimen to adolescents in public schools, public health clinics, and private sector settings.
The analysis compared the predicted costs of administering two-dose regimens with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.